RAF1 and cholangiocarcinoma: Downregulation of the Pi3k/Akt/mTOR pathway by the Pi3k inhibitor Apitolisib or the Ras/Raf/MEK/ERK pathway by the MEK inhibitor Refametinib did not enhance the anti-tumor effect Tivantinib had on the viability of CC cells.